Author

Reina Makino

Institution: Ono Pharmaceutical (Japan)

Observed institution: Ono Pharmaceutical (Japan)

OpenAlex ID: A5111295946

Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

2024 · Narikazu Boku, Takeshi Omori, et al. · Gastric Cancer · 54

Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in Japan: a retrospective database cohort study

2024 · Takaki Yoshikawa, Yorifumi Kikko, et al. · Gastric Cancer · 2

Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications

2026 · Hiroyuki Ichida, Takaharu Nakao, et al. · CPT Pharmacometrics & Systems Pharmacology

Works count: 3

Citation count: 56

H-index: 2

I10-index: 1